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ttp://dx.doi.org/10.1016/j.ajpath.2014.04.012Fatty acid synthase is up-regulated in a variety of cancers, including prostate cancer. Up-regulation of
fatty acid synthase not only increases production of fatty acids in tumors but also contributes to the
transformed phenotype by conferring growth and survival advantages. In addition, increased fatty acid
synthase expression in prostate cancer correlates with poor prognosis, although the mechanism(s) by
which this occurs are not completely understood. Because fatty acid synthase is expressed at low levels
in normal cells, it is currently a major target for anticancer drug design. Fatty acid synthase is normally
found in the cytosol; however, we have discovered that it also localizes to the nucleus in a subset of
prostate cancer cells. Analysis of the fatty acid synthase protein sequence indicated the presence of a
nuclear localization signal, and subcellular fractionation of LNCaP prostate cancer cells, as well as
immunoﬂuorescent confocal microscopy of patient prostate tumor tissue and LNCaPs conﬁrmed nuclear
localization of this protein. Finally, immunohistochemical analysis of prostate cancer tissue indicated
that nuclear localization of fatty acid synthase correlates with Gleason grade, implicating a potentially
novel role in prostate cancer progression. Possible clinical implications include improving the accuracy
of prostate biopsies in the diagnosis of low- versus intermediate-risk prostate cancer and the uncov-
ering of novel metabolic pathways for the therapeutic targeting of androgen-independent prostate
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Disclosures: None declaredFatty acid synthase (FASN) is a large, multifunctional
enzyme that is responsible for the de novo synthesis of long
chain fatty acids. Because it is typically unnecessary for
FASN to produce fatty acids in cells because of sufﬁcient
intake of fatty acids in the diet, FASN is expressed at low
levels in most normal tissues. However, FASN expression
has been found to be up-regulated in many cancers1, and in
several cancers, including prostate cancer, it correlates with
poor prognosis.2e4 In immortalized human prostate epithelial
cells and in the LNCaP human prostate cancer cell line,
FASN expression increases cell proliferation and growth in
soft agar and results in androgen receptor-dependent forma-
tion of invasive adenocarcinoma.5 That same study also re-
ported that transgenic expression of FASN in mouse prostate
epithelial cells led to prostatic intraepithelial neoplasia and
protected against castration- and chemotherapeutic-induced
apoptosis, whereas siRNA knockdown of FASN in LNCaP
cells resulted in apoptosis.5stigative Pathology.
.A number of theories have been proposed to explain
FASN up-regulation in cancers, which ultimately results in a
metabolic shift toward producing large amounts of fatty
acids. One such theory is related to the Warburg effect, a
phenomenon that is observed in most cancers. This involves
an increase in the use of the glycolytic pathway for energy
production, which also leads to an increase in the substrates
Nuclear Fatty Acid Synthaseused in de novo fatty acid synthesis.6,7 It has also been
postulated that fatty acid production is necessary to supply
the structural components of the cell membrane for actively
proliferating tumor cells.7 Alternatively, in the hypoxic
environment of tumors, FASN may provide a means for
balancing redox through its ability to consume reducing
molecules such as NADPH.5e7 Regardless of the exact
function(s) of FASN in carcinogenesis, it clearly contributes
to the transformed phenotype by conferring growth and
survival advantages.
Although FASN is an attractive therapeutic target in the
treatment of cancer because of its low level of expression in
normal tissues and concomitant overexpression in many can-
cers, small molecule inhibitors designed against this oncogenic
protein have experienced limitations in their effectiveness
because of poor bioavailability, lack of speciﬁcity, and sig-
niﬁcant side effects.7e10 To improve on therapeutics to target
FASN, it is important to understand the precise mechanisms
by which FASN promotes carcinogenesis.
The normal location of FASN in the cytoplasm is
consistent with its known role in fatty acid synthesis.
However, when we were examining immunohistochemical
images of FASN expression in prostate cancer specimens,
we observed that FASN appeared to be localized to the
nucleus in a subset of the tumor cells. Through examination
of an online database (The Human Protein Atlas, http://
www.proteinatlas.org, last accessed March 15, 2013) that
contains patient prostate cancer sections subjected to multiple
antibodies raised against FASN, nuclear localization of FASN
in a subset of tumor cells was again observed. We sought to
conﬁrm the nuclear localization of FASN in prostate cancer
and to determine whether it could be used as a clinical marker
for this disease. To our knowledge, this is the ﬁrst observation
of FASN localizing to the nucleus in any cell type.
Materials and Methods
Immunoblot Analysis
LNCaP whole-cell extracts (30 mm) and nuclear extracts
isolated with hypotonic buffer were run on an 8% SDS-
PAGE gel, transferred to polyvinylidene diﬂuoride mem-
brane, blocked in 5% bovine serum albumin, incubated with
a monoclonal anti-FASN antibody (dilution 1:2500; BD
Biosciences, San Jose, CA,), washed in Tris-buffered saline
and Tween 20, incubated with anti-mouse antibody (Sigma-
Aldrich, St. Louis, MO), washed, incubated with electro-
chimiluminescence reagent, and exposed to ﬁlm. Treatments
with 1 nmol/L testosterone and/or 17b-estradiol (Sigma-
Aldrich) were performed, and quantitation was accom-
plished with ImageJ version 1.47v (NIH, Bethesda, MD).
Immunoﬂuorescence and Confocal Microscopy
Frozen sections of Gleason 7 prostate cancer specimens
[acquired from the University of Pittsburgh Health SciencesThe American Journal of Pathology - ajp.amjpathol.orgTissue Bank and approved by the University of Pittsburgh
Institutional Review Board (protocol 0506140)] or subcon-
ﬂuent LNCaP cells were used. Slides were ﬁxed in 2%
paraformaldehyde, incubated in 0.1% Triton X-100, rehy-
drated, blocked in 2% bovine serum albumin, washed in
0.5% bovine serum albumin, incubated with monoclonal
anti-FASN clone 3F2-1F3 (dilution 1:250; Sigma-Aldrich) in
0.5% bovine serum albumin, washed, incubated with Alexa
Fluor 488 anti-mouse (3.5 mg/mL; Invitrogen, Eugene, OR),
washed, incubated with Draq5 nuclear stain (dilution 1:1000;
eBioscience, Inc., San Diego, CA), and covered with a
coverslip. Confocal microscopy was performed on a Leica
(Wetzlar, Germany) TCS SP confocal microscope at 63
magniﬁcation in the University of Pittsburgh Cell and Tissue
Imaging Facility.
Immunohistochemistry
Formalin-ﬁxed, parafﬁn-embedded prostate cancer tissue of
various Gleason grades from 45 patients who had undergone
radical prostatectomy were obtained from the University of
Pittsburgh Health Sciences Tissue Bank and approved by the
University of Pittsburgh Institutional Review Board (protocol
PR011110523). Two samples of benign prostate glands were
also obtained from deceased tissue donors. Slides were heated
in a 60C oven, deparafﬁnized, placed in boiling 0.01 mol/L
citrate buffer (PolyScientiﬁc, Bay Shore, NJ) for antigen
retrieval, and incubated in 3% H2O2 to block endogenous
peroxidase activity. TheM.O.M. kit (Vector Laboratories Inc.,
Burlingame, CA) was used for the application of antibody
according to the manufacturer’s instructions. Slides were
incubated with primary anti-FASN (dilution 1:250; Sigma-
Aldrich), ﬂooded with NovaRED solution (Vector Labora-
tories Inc., Burlingame, CA) as per the manufacturer’s
instructions, counterstained with hematoxylin, dehydrated,
applied coverslip with Permount mounting medium (Thermo
Fisher Scientiﬁc, Waltham, MA), and air-dried overnight.
Correlation of Nuclear FASN with Gleason Grade
Final pathology of each specimen was conﬁrmed in a
blinded review with a genitourinary pathologist (A.V.P.).
Each slide was digitally scanned as a whole slide image with
the use of ScanScope XT (Aperio, Vista, CA) and viewed
with Aperio ImageScope version 11.2.0.780. Each specimen
was examined for the region with the most representative
pathology and the most consistently highest staining in-
tensity, which was then used for the analysis. Of the 49
original prostatectomy samples, 4 were excluded from being
analyzed because of either signiﬁcant staining artifact or
small and poorly preserved cancer regions.
The immunohistochemical Nuclear Image Analysis
algorithm version 9.1 (Aperio) was used to quantify the
percentage of mild, moderate, and strongly staining nuclei.
The default values for the parameters nuclear stain and
positive stain provided by Aperio for the detection of the2157
Figure 1 The online program cNLS Mapper indicates the presence of an
NLS within the FASN protein sequence (A), immunoblot analysis of LNCaP
nuclear lysates indicates that FASN is localized to the nucleus in LNCaP cells
(B), and overall expression of FASN is stimulated by testosterone and/or
17b-estradiol (C), but nuclear expression is abolished in the presence of
17b-estradiol. A: The FASN amino acid sequence is shown with the NLS in
bold italics and underlined. B: Immunoblot analysis of FASN expression in
LNCaP whole cell and nuclear extracts. Levels of nuclear FASN in LNCaPs can
vary according to the passage. C: LNCaP cells were treated with 1 nmol/L
testosterone, 1 nmol/L 17-b estradiol, or vehicle alone for 4.5 hours.
Whole-cell or nuclear extracts were run and anti-FASN, an antibody
detecting beta actin, and an antibody detecting the cytoplasmic marker
GAPDH are shown. E2, 17-b estradiol; ETOH, ethanol; GAPDH, glyceralde-
hyde-3-phosphate dehydrogenase; T, testosterone; WC, whole-cell extract.
Madigan et albrown staining were used. In addition, the default values
(range, 0 to 255) for the weak (210 to 189), moderate (188
to 163), and strong (162 or less) staining intensity thresholds
were not changed. These are graded on an inverse scale of
light transmission, with the value of 255 representing no
staining, or high light transmission, and 0 representing the
darkest staining possible. The algorithm parameters of cur-
vature threshold (2), minimum nuclear size in square mi-
crometers (30 mm2), maximum nuclear size in square
micrometers (500 mm2), minimum roundness (0.4), mini-
mum compactness (0.3), and minimum elongation (0.2)
were modiﬁed during an initial validation process to pro-
duce the most consistent and accurate results across the
pathological spectrum of the samples.
The scoring output by the image analysis software was
reported as a percentage of nuclei staining at each threshold.
This was converted into a composite nuclear staining score
to account for the varying staining intensities and to allow
appropriate comparison between specimens. The conversion
required multiplying the weak percentage by 1, the mod-
erate percentage by 2, and the strong percentage by 3, and
then summing these amounts for a maximum score of 300.
The output results of the algorithm were conﬁrmed in a
second blinded review by a genitourinary pathologist
(A.V.P.). Statistical analysis was performed with STATA
version 12.1 (StataCorp LP, College Station, TX). A two-
sample Wilcoxon rank sum (ManneWhitney) test was
performed to detect a difference in the median percentages
of strongly staining nuclei between different cancer grades.
Results
Presence of an NLS in FASN and Prediction of Nuclear
Localization
After observing nuclear localization of FASN in a subset of
prostate cancer cells via immunohistochemistry, we wanted
to examine whether FASN contained a nuclear localization
signal (NLS). We used the online program cNLS Mapper to
determine the presence of an NLS in the FASN protein
sequence.11 This program found a monopartite NLS,
beginning at amino acid 2043 (Figure 1A), which would
allow for nuclear localization of FASN.
In addition, we used the FASN protein sequence as input
into the cell localization prediction tool WoLF PSORT.12
This program predicts cytoplasmic and/or nuclear localiza-
tion of proteins on the basis of sorting signals, amino acid
composition, and functional motifs.12 This program also
predicted both nuclear and cytoplasmic localization of
FASN in cells.
Evidence for Nuclear Localization of FASN in LNCaP
Prostate Cancer Cells
Next, we examined whether cultured prostate cancer cells
expressed nuclear FASN. Nuclear and whole-cell lysates2158were prepared from the LNCaP prostate cancer cell line and
analyzed for FASN expression. Immunoblot analysis found
that the 270-kDa FASN is expressed in LNCaP whole-cell
lysates as well as nuclear extracts (Figure 1B). The nuclear
extracts were determined to be free of cytoplasmic
contamination because of the absence of the cytoplasmic
protein glyceraldehyde-3-phosphate dehydrogenase. The
LNCaP nuclear extracts were also enriched for the nuclear
marker EZH2 compared with the whole-cell lysates. Nuclear
and whole-cell lysates from the DU145, PC3, and BPH1
prostate cell lines were also examined for nuclear FASN via
immunoblot analysis; however, these prostate cell lines do
not express nuclear FASN (data not shown) (Supplemental
Figure S1).
We then wanted to determine what regulated nuclear
localization of FASN. Hormones, growth factors, and
cytokines are known to regulate FASN expression.13 To
determine whether hormone treatment could induce nuclear
localization of FASN, LNCaP cells were treated with 1
nmol/L testosterone (or the testosterone analogue R1881;
data not shown), 1 nmol/L testosterone plus 1 nmol/L 17b-
estradiol, 17b-estradiol alone, or vehicle (ethanol) alone for
4.5 hours. Cells were harvested, nuclear and whole-cell
lysates were prepared as described above, and immunoblot
analysis for FASN was performed (Figure 1C). Treatment
with testosterone increased overall expression of FASN
protein by 54%, and nuclear localization of FASN was
increased similarly by 59%. However, the addition of 17b-
estradiol almost completely abolished nuclear localization
of FASN, whereas treatment with both testosterone and
17b-estradiol or with 17b-estradiol alone increased overall
expression of FASN protein by 140% and 119% overajp.amjpathol.org - The American Journal of Pathology
Figure 2 Confocal microscopy conﬁrms nuclear localization of FASN in a subset of prostate cancer cells. FASN (green), Draq5 nuclear stain (blue), and the
merge of the two stainings.
Nuclear Fatty Acid Synthasevehicle alone, respectively. LNCaP cells were also exposed
to hypoxic conditions (1% O2), which induces a cytokine
response, or treated with epidermal growth factor; however,
these treatments/conditions did not induce nuclear locali-
zation of FASN (data not shown). These data suggest that
17b-estradiol is able to regulate nuclear localization of
FASN protein.
Conﬁrmation of Nuclear Localization of FASN in
Prostate Cancer Cells
To further conﬁrm nuclear localization of FASN in pros-
tate cancer cells, we performed immunoﬂuorescence on
prostate cancer specimens obtained from patients. Con-
focal microscopic analysis of the immunoﬂuorescence on
patient prostate tumor tissues showed in a three-
dimensional manner that FASN localizes to the nucleus
in a subset of cancer cells (Figure 2). In addition, immu-
noﬂuorescence for FASN was performed on cultured
LNCaP prostate cancer cells, and confocal analysis of
these cells also showed localization of FASN to the nu-
cleus (Supplemental Figure S2).Table 1 Results of Immunohistochemical Nuclear Staining Analysis
Pathology
Median co
nuclear sc
Benign prostate epithelium 0.43
High-grade prostate intraepithelial neoplasia 3.63
Prostate cancer
Gleason pattern 3 þ 3 Z 6 3.39
Gleason pattern Z 7 (combined) 22.73
3 þ 4 Z 7 20.19
4 þ 3 Z 7 26.36
Gleason pattern 4 þ 4 Z 8 or higher 43.59
Negative controls (combined) 0
Gleason pattern 3 þ 3 Z 6 0
Gleason pattern 3 þ 4 Z 7 0
Composite nuclear score combines the percentage of nuclei that have mild, mo
The American Journal of Pathology - ajp.amjpathol.orgCorrelation of Nuclear FASN with Gleason Grade
Finally, we wanted to determine whether nuclear FASN
expression correlated with Gleason grade via immunohisto-
chemical analysis. Forty-one cancer specimens were stained,
and four patient samples were used as negative controls with
secondary antibody staining only. There were two Gleason
score (GS) 3þ 3Z 6 negative controls and twoGS 3þ 4Z 7
negative controls. The 41 tumor specimens were composed of
6 specimens GSZ 6, 26 specimens GSZ 7, and 9 specimens
GS  8, with 2 additional specimens from benign tissue do-
nors. High-grade prostatic intraepithelial neoplasia (HGPIN)
regions (n Z 21) were found throughout the already used
cancer specimens and were also analyzed (Table 1).
Representative analysis outputs by the nuclear staining
algorithm for the negative controls and various Gleason pat-
terns are shown in Figure 3. The median composite nuclear
scores for GSZ 6 and GSZ 7 negative controls were 0 (0 to
0) and 1.6 (0 to 3.2), respectively. The median composite
nuclear score was 0.43 (95% CI, 0.11e0.74) for the benign
glands, 3.63 (95% CI, 2.41e6.58) for the HGPIN regions,
3.39 (95% CI, 0.03e4.96) for GS Z 6, 22.73 (95% CI,mposite
ore 95% CI
No. of
specimens
0.11e0.74 2
2.41e6.58 21
41
0.03e4.96 6
15.09e26.22 26
14.09e26.03 22
14.28e47.93 4
4.02e60.13 9
0e3.2 4
0 2
0e3.2 2
derate, and strong intensity staining for a maximum score of 300.
2159
Figure 3 Immunohistochemical staining and automated analysis output. Gleason score 3 þ 4Z 7 negative control with only secondary antibody staining
(A) and the resulting scoring output (E) from the Nuclear Image Analysis algorithm version 9.1 (Aperio). The lines drawn on each section are examples of areas
chosen to be anaylzed by the Aperio software. Dashed lines represent areas to be removed from the analysis. A: Red arrows indicate dark nuclei that are still
scored as negative because of lack of brown staining. C and D: Yellow arrows indicate speciﬁc nuclear localization of FASN. EeH: Blue output coloring from
the algorithm indicates no nuclear staining, whereas yellow, orange, and red indicate mild, moderate, and strong nuclear staining, respectively. Gleason
pattern 3 þ 3Z 6 prostate cancer stained with anti-FASN antibody (B) and scoring output (F), Gleason pattern 3 þ 4Z 7 prostate cancer stained with anti-
FASN antibody (C) and scoring output (G), and Gleason pattern 4 þ 4 Z 8 prostate cancer stained with anti-FASN antibody (D) and scoring output (H).
Figure 4 Median and composite nuclear score by pathological group.
GS, Gleason score; HGPIN, high-grade prostatic intraepithelial neoplasia.
Madigan et al15.09e26.22) for GSZ 7, and 43.59 (95% CI, 4.02e60.13)
for GS  8 (Figure 4). The skewness and kurtosis test for
normality, as well as the ShapiroeWilk normality test,
conﬁrmed a nonparametric distribution of the results.
A signiﬁcant increase existed in nuclear FASN staining
between GS Z 6 and cancers that were GS  7
(P Z 0.0008), between only GS Z 6 compared with
GS Z 7 cancers (P Z 0.0005), and between GS Z 6 and
GS  8 cancers (P Z 0.0251). No difference was found
between HGPIN and GS Z 6 cancers (P Z 0.255). Sig-
niﬁcant increases in FASN nuclear staining were found
between HGPIN and GS Z 7 (P < 0.0001) and between
HGPIN and GS  8 (P Z 0.0062). The increase between
GS Z 7 and GS 9 to 10 cancers was also signiﬁcant
(PZ 0.004). Finally, as an extension of the Wilcoxon rank
sum test, we conﬁrmed a signiﬁcant trend for the composite
nuclear scores across each Gleason score group (P < 0.001).
Discussion
This is the ﬁrst report of FASN localization to the nucleus.
Because this phenomenon occurs almost exclusively in2160tumor cells and increases in frequency along with disease
grade implies that mislocalization of this protein to the
nucleus is involved in prostate carcinogenesis and progres-
sion and may be a novel marker of more aggressive disease.ajp.amjpathol.org - The American Journal of Pathology
Nuclear Fatty Acid SynthaseOur observation was supported by bioinformatic analysis of
the FASN protein sequence, which showed the presence of a
previously unreported NLS sequence, and nuclear frac-
tionation of the LNCaP cell line which indicated that at least
a portion of the FASN expressed in these cells is localized to
the nucleus. The DU145, PC3, and BPH1 prostate cell lines
were also examined for nuclear FASN expression via nu-
clear fractionation and immunoblot analysis; however, these
cell lines did not express nuclear FASN. LNCaP cells are
arguably more representative of true prostate cancer than the
other lines (eg, they express the androgen receptor, prostate-
speciﬁc antigen, prostate-speciﬁc membrane antigen, and
prostatic acid phosphatase). In addition, it is known that
molecular changes occur in cells when they are taken from
patients and grown in culture, so perhaps nuclear FASN is lost
in some cell lines when grown in culture. We then veriﬁed
nuclear localization of FASN in a subset of prostate cancer
cells via confocalmicroscopy on prostate cancer patient tissue
specimens and in cultured LNCaP prostate cancer cells.
Importantly, we demonstrated that 17b-estradiol abolished
nuclear localization of FASN, giving insight into regulation of
nuclear FASN. Hormones are known to regulate FASN.Most
notably, testosterone induces FASN expression. The regula-
tion of FASN by 17b-estradiol is likely complex, and we plan
to investigate this further in the future. Finally, we used digital
imaging and automated nuclear analysis and quantitation to
indicate a signiﬁcant relationship between the frequency and
intensity of nuclear FASN expression and Gleason grade; we
found minimal to no nuclear staining in benign prostate
epithelial cells, HGPIN, and low-grade prostate tumor cells
(Gleason score Z 6). These ﬁndings are consistent with a
previous report that found a signiﬁcant increase in the
expression of FASN mRNA in cancers with GS Z 7 and
above compared with low-grade disease.14
Previous studies do exist with evidence to support the
concept of FASN nuclear localization. In a large-scale report
published in 2006, Olsen et al15 looked at the subcellular
localization andphosphorylation status ofproteins inHeLacells
in the presence or absence of epidermal growth factor treatment.
The investigators found that treatment with epidermal growth
factor induced nuclear accumulation of FASN. In a separate
study examining bindingpartners of nuclear versus cytoplasmic
histone deacetylase 5,Greco et al16 showed that FASN interacts
with the predominantly nuclear form of histone deacetylase 5.
Moreover, another large-scale study showed that FASN in-
teracts with Sirtuin 7, a primarily nuclear protein.17 These
ﬁndings, along with what we have shown in the present study,
provide evidence to support the idea that FASN can localize to
the nucleus in speciﬁc cells under certain conditions. There are
two reports of perinuclear localization of FASN, one as part of
the pathogenesis of dengue virus and the second in oral squa-
mous cell carcinoma cells18,19; however, this is different from
the nuclear localization that we observe here.
The potential function of nuclear FASN is largely un-
known. As reviewed by Rossi et al,20 knockdown of FASN
results in inhibition of DNA synthesis, implicating a potentialThe American Journal of Pathology - ajp.amjpathol.orgnuclear role for FASN. Alternatively, the crystal structure of
mammalian FASN indicated that this large protein contains a
conserved methyltransferase domain.21 It is unknown
whether this methyltransferase domain is functional, but, if it
is, nuclear FASN may be contributing to the altered epige-
netic landscape in prostate cancer via DNA methylation or
methylation of other nuclear proteins such as histones.
Furthermore, one of the enzymatic domains of FASN that is
used during fatty acid synthesis is an acetyl-transferase.
Therefore, another potential function for nuclear FASN
may be through modiﬁcation of chromatin via acetylation.
The immunohistochemical analysis of nuclear FASN
expression in the different Gleason grade prostate cancers
used automated analysis technology. There are an increasing
number of reports that use the many different options for
automated analysis, including studies speciﬁcally using the
Aperio image analysis software to investigate nuclear pro-
teins.22,23 The beneﬁts of an automated software package
include decreased interobserver variability and increased
reproducibility, also known as precision, because the pa-
rameters do not change between specimens or interpreters.24
Although these algorithms still require validation with
another form of measurement to conﬁrm their accuracy,
usually from correlation with a pathologist’s ﬁndings, the
removal of some of the biases inherent in visual interpretation
increases precision and should theoretically improve the
overall application of the results. In fact, a recent report found
that, by using image analysis tools, the quantifying of nuclear
proteins in breast cancer was improved and allowed for lower
thresholds to be used to predict tumor responsiveness to
certain hormone therapies.23 Because the degree of nuclear
staining can be difﬁcult to interpret, especially in the context
of concurrent cytoplasmic staining, we consider the use of
our automated algorithm as a major strength to our ﬁndings.
Two areas exist in which nuclear localization of FASN could
have novel effects on the management of prostate cancer. The
ﬁrst is in improving the accuracy of prostate needle biopsies in
the diagnosis of low- versus intermediate-risk prostate cancer.
The second area in which this discoverymay prove beneﬁcial is
in the treatment of castration-resistant or androgen-independent
prostate cancer. The normal regulatory control of FASN ex-
pression is lost in more advanced cancers and is often no longer
manipulated by androgens. In addition, in human prostate can-
cer specimens, as well as in vitro and in vivo models, FASN
expression was highest in androgen-independent cells and in
fact represented the progression from androgen-dependent
to androgen-independent cancers.25 This same study also con-
ﬁrmed that inhibition of FASN led to death of these cells. It
would be most useful to discover the role of nuclear locali-
zation of FASN in this progression, and whether there are any
opportunities to prevent it fromoccurring. In addition, because
no cure for androgen-independent prostate cancer is available,
a therapy that targets FASN directly, especially one that is
speciﬁcally targeted to the nucleus, could be quite effective
and potentially decrease side effects from nonspeciﬁc inhibi-
tion of FASN in the cytoplasm of normal cells.2161
Madigan et alIn conclusion, we report here the novel observation that
FASN can localize to the nucleus in a subset of prostate
cancer cells. Although overall FASN expression is already
known to correlate with poor prognosis in prostate cancer,
we show that nuclear localization of FASN correlates with
Gleason grade. Because it is still unclear exactly how FASN
promotes tumorigenesis, it is important to investigate the
function of nuclear FASN, because the nuclear form of this
protein may promote carcinogenesis. Nuclear FASN
expression reaches signiﬁcant levels in intermediate- and
high-grade cancers, potentially implicating nuclear FASN as
an important factor in the progression of prostate cancer
from clinically indolent to clinically signiﬁcant. Future in-
vestigations are required to examine how nuclear FASN is
regulated, what its function is within the nucleus, and how
these factors may be used to develop more speciﬁc thera-
peutic agents to target aggressive prostate cancer.
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